Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Miranda R. Cai"'
Autor:
Mingzhu Zhu, Shane Cloney-Clark, Sheau-line Feng, Anand Parekh, Drew Gorinson, David Silva, Paul Skonieczny, Adjele Wilson, Raj Kalkeri, Wayne Woo, Miranda R. Cai, Louis Fries, Greg Glenn, Joyce S. Plested
Publikováno v:
Microorganisms, Vol 11, Iss 7, p 1789 (2023)
As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critica
Externí odkaz:
https://doaj.org/article/7031ad406929446f93365e8f5df4cb5a
Autor:
Plested, Mingzhu Zhu, Shane Cloney-Clark, Sheau-line Feng, Anand Parekh, Drew Gorinson, David Silva, Paul Skonieczny, Adjele Wilson, Raj Kalkeri, Wayne Woo, Miranda R. Cai, Louis Fries, Greg Glenn, Joyce S.
Publikováno v:
Microorganisms; Volume 11; Issue 7; Pages: 1789
As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::f8fde002b533d5297f5043df799bc52d
Autor:
Katherine Smith, Karim Hegazy, Miranda R. Cai, Irene McKnight, Matthew D. Rousculp, Katia Alves
Publikováno v:
Vaccine.
BackgroundNVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6ff1fc7410a2593db3f2727a60e238
https://doi.org/10.1016/j.vaccine.2023.05.016
https://doi.org/10.1016/j.vaccine.2023.05.016
Autor:
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R. Cai, Gordon Chau, Shane Cloney-Clark, Mark Eickhoff, Raj Kalkeri, Irene McKnight, Joyce Plested, Mingzhu Zhu, Lisa Dunkle
BackgroundTo combat the SARS-CoV-2 pandemic, multiple vaccines using different manufacturing platforms have been developed, including NVX-CoV2373 (an adjuvanted recombinant protein vaccine). As SARS-CoV-2 variants have emerged, some of which evade va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64e3bd609836d2a17a83aefdd3b41b6a
https://doi.org/10.1101/2023.03.16.23287030
https://doi.org/10.1101/2023.03.16.23287030
